# SELECT MDS-1 (NCT04797780)

> Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04797780
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Syros Pharmaceuticals
- Conditions: Myelodysplastic Syndromes
- Interventions: Tamibarotene; Placebo; Azacitidine
- Enrollment: 246
- Primary outcome: Percentage of Participants With Complete Remission (CR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- YouTube: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=select-mds-1-nct04797780

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04797780", "email": "<work email>"}; the inbox owner confirms by the emailed link.